Since PD-L1 largely determines the efficacy and effectiveness of cancer immunotherapies, the development of ATP11B-targeting drugs is highly promising for anti-pancreatic cancer immunity [255]. The gene discussed is ATP11B; the disease is familial pancreatic carcinoma.